Journal of Hematology, ISSN 1927-1212 print, 1927-1220 online, Open Access
Article copyright, the authors; Journal compilation copyright, J Hematol and Elmer Press Inc
Journal website https://www.thejh.org

Case Report

Volume 13, Number 1-2, April 2024, pages 46-51

Clinical Efficacy of Programmed Cell Death Ligand 1 Antibody in Treatment of Extranodal Natural Killer/T-Cell Lymphoma With Hemophagocytic Lymphohistiocytosis

Figures

Figure 1.
Figure 1. Pathological images of the nasal cavity of the patient at the time of diagnosis. HE: hematoxylin and eosin stain; EBER: EBV-encoded RNA.
Figure 2.
Figure 2. The PET/CT images of the patient at the time of diagnosis. PET/CT: positron emission tomography/computed tomography.
Figure 3.
Figure 3. Treatment timeline of the patient. ENKTCL: extranodal natural killer/T-cell lymphoma; HLH: hemophagocytic lymphohistiocytosis; PR: partial response; CR: complete response; MTX: methotrexate; DEP regimen: docetaxel, epirubicin, and cisplatin; q3w: every three weeks; SMILE regimen: steroid, methotrexate, ifosfamide, l-asparaginase, and etoposide; PD: progression of disease; PD-L1: programmed cell death ligand 1.

Table

Table 1. Summary of the Targeted Drugs Applied in Adult sHLH
 
ReferenceTargetsSecondary causeEfficacy
sHLH: secondary hemophagocytic lymphohistiocytosis; IL-1R: interleukin-1 receptor; PD-1: programmed cell death protein 1; PD-L1: programmed cell death ligand 1; JAK: Janus kinase; OS: overall survival; DoR: duration of response; CRR: complete response rate; EBV: Epstein-Barr virus; MDS: myelodysplastic syndrome; ENKTCL-LAHS: extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis; ENKTCL: extranodal natural killer/T-cell lymphoma.
Miettunen et al, 2011 [17]IL-1RRheumatic diseasesOS 2 - 40 months
Keith et al, 2012 [18]CD52Systemic lupus erythematosusDoR 19 months
Liu et al, 2020 [16]PD-1EBV-associated HLHOS 5 - 18.9 months
He et al, 2023 [19]PD-1 + chemotherapyENKTCL-LAHSOS 5.2 months
Song et al, 2023 [20]JAK1/2Rheumatic diseases/lymphoma/pregnancy/MDSORR 50%
Dufranc et al, 2020 [21]IL-6RInfection/ autoimmune disordersCRR 88.9%
Present casePD-L1ENKTCLDoR 44 months